T. N. Gert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
T. N. Gert has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anna N. Kirienko
Russian Research Institute of Hematology and Transfusiology
2 shared publications - Daria V. Kustova
Russian Research Institute of Hematology and Transfusiology
2 shared publications - Ekaterina V. Motyko
Russian Research Institute of Hematology and Transfusiology
2 shared publications - Irina S. Martynkevich
Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya ul., Saint Petersburg, Russian Federation, 191024
2 shared publications - Irina Viktorovna Leppyanen
All-Russia Research Institute for Agricultural Microbiology
2 shared publications - Vasily A. Shuvaev
AF Tsyb Medical Radiological Research Center, branch of the NMRC of Radiology, 4 Koroleva ul., Obninsk, Kaluga Region, Russian Federation, 249036
2 shared publications
Latest Publications
- Open Access
- 23 March 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (1) , 80-87
NGS analysis of the mutational profile of patients with Ph-negative myeloproliferative neoplasms
Introduction. The identification of driver mutations in the JAK2, CALR, and MPL genes is a gold standard approach in the molecular diagnosis of patients with Ph-negative myeloproliferative neoplasms (Ph-MPNs). However, such patients are characterized by a heterogenous genomic landscape. Standard molecular genetic methods cannot be used to identify most somatic mutations, thus failing to provide a comprehensive understanding of the course and prognosis of Ph-MPNs and to confirm the clonality of the disease in patients with triple-negative status. The next generation sequencing (NGS) technology allows simultaneous analysis of an extensive panel of genes and identification of both pathogenic and driver mutations.Aim. To evaluate the possibility of using NGS to study the mutational status of patients with Ph-negative MPNs and to analyze the effect of identified pathogenic mutations on patient survival.Materials and methods. The study included 83 patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis aged from 19 to 85 years (the median onset age of 51 years). For all patients, sequencing was performed using a myeloid panel of 118 genes with an average reading depth of 1000x on MiSeq (Illumina, USA). The clinical significance of the mutations was determined using the COSMIC and Franklin databases. The survival rate was analyzed using the Kaplan–Meyer method followed by assessment of statistical significance using the Cox-Mantel test in the GraphPad Prism 8 environment.Results. Pathogenic mutations in 23 genes were detected in 39 (46%) patients out of the total cohort of patients. The most frequent mutations were detected in the ASXL1 gene in 25% of patients, which reduced event-free survival by 50.3% (Me = 7.83 years vs 15.75 years). The pathogenic mutations identified in other genes combined with mutations in driver genes also decreased event-free survival compared to patients with isolated driver mutations. Two or more pathogenic mutations significantly reduced event-free survival compared to patients with only one pathogenic mutation. The NGS method was also capable of identifying pathogenic mutations in 8 out of 10 triple-negative patients studied, thus confirming the clonality of the disease.Conclusions. The next-generation sequencing (NGS) method using a panel of 118 genes is an effective tool in identifying predictively significant mutations important for selecting the most effective personalized therapy to achieve hematologic response.
- 23 March 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (1) , 80-87
Open AccessNGS analysis of the mutational profile of patients with Ph-negative myeloproliferative neoplasms
Introduction. The identification of driver mutations in the JAK2, CALR, and MPL genes is a gold standard approach in the molecular diagnosis of patients with Ph-negative myeloproliferative neoplasms (Ph-MPNs). However, such patients are characterized by a heterogenous genomic landscape. Standard molecular genetic methods cannot be used to identify most somatic mutations, thus failing to provide a comprehensive understanding of the course and prognosis of Ph-MPNs and to confirm the clonality of the disease in patients with triple-negative status. The next generation sequencing (NGS) technology allows simultaneous analysis of an extensive panel of genes and identification of both pathogenic and driver mutations.Aim. To evaluate the possibility of using NGS to study the mutational status of patients with Ph-negative MPNs and to analyze the effect of identified pathogenic mutations on patient survival.Materials and methods. The study included 83 patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis aged from 19 to 85 years (the median onset age of 51 years). For all patients, sequencing was performed using a myeloid panel of 118 genes with an average reading depth of 1000x on MiSeq (Illumina, USA). The clinical significance of the mutations was determined using the COSMIC and Franklin databases. The survival rate was analyzed using the Kaplan–Meyer method followed by assessment of statistical significance using the Cox-Mantel test in the GraphPad Prism 8 environment.Results. Pathogenic mutations in 23 genes were detected in 39 (46%) patients out of the total cohort of patients. The most frequent mutations were detected in the ASXL1 gene in 25% of patients, which reduced event-free survival by 50.3% (Me = 7.83 years vs 15.75 years). The pathogenic mutations identified in other genes combined with mutations in driver genes also decreased event-free survival compared to patients with isolated driver mutations. Two or more pathogenic mutations significantly reduced event-free survival compared to patients with only one pathogenic mutation. The NGS method was also capable of identifying pathogenic mutations in 8 out of 10 triple-negative patients studied, thus confirming the clonality of the disease.Conclusions. The next-generation sequencing (NGS) method using a panel of 118 genes is an effective tool in identifying predictively significant mutations important for selecting the most effective personalized therapy to achieve hematologic response.
- Open Access
- 1 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 45-60
Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia
Background. Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved molecular response is observed in 15–30 % of patients. Mutations in the BCR::ABL kinase domain are one of the most common mechanisms for the development of resistance to tyrosine kinase inhibitors.Aim. To conduct a retrospective analysis of the BCR::ABL kinase domain mutational profile in patients with CML observed at the Russian Research Institute of Hematology and Transfusiology from 2012 to 2023. To assess the impact of mutations type and number on the rate of achieving a major molecular response (MMR). To study the risk of MMR loss depending on the therapy line and existing mutational status.Materials and methods. 1831 patients with CML were examined at different times. The mutational status of the BCR::ABL kinase domain was analyzed by direct Sanger sequencing. A standard cytogenetic study was carried out using GTG banding technology with the analysis of at least 20 metaphase plates.Results. Mutations in the BCR::ABL kinase domain were identified in 27.6 % of the total studied patients. The most common mutation, 6.3 % in the overall group or 22.7 % among patients with mutations, was the T315I mutation. Additional chromosomal aberrations (ACAs) were detected in Ph-positive cells in 20.5 % of patients, in Ph-negative clones in 3.9 % of cases (p = 0.0001). The frequency of ACAs detection did not statistically significantly differ (p = 0.25) between patients with BCR::ABL mutations (23.5 %) and with a negative mutation status (17.7 %), and the presence of mutations in the kinase domain did not correlate with ACAs in Ph-positive clones (p = 0.73). However, the frequency of T315I mutation detection in Ph-positive cells had significant differences: 40.9 % in combination with ACAs and 21 % without ACAs (p = 0.032). Patients with the T315I mutation had significantly worse MMR than patients with mutations in other BCR::ABL regions (p = 0.04) and patients without mutations (p = 0.02). The probability of MMR achieving did not differ significantly between patients with different numbers of BCR::ABL mutations (p = 0.14). Loss of MMR occurred more often in patients with mutations (p = 0.04) and not depend on the line of therapy (p = 0.03).Conclusion. For complete monitoring and optimal choice of therapy, CML patients require not only monitoring of BCR::ABL relative expression level, but also standard cytogenetic and analysis of the mutational status.
- 1 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 45-60
Open AccessRetrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia
Background. Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved molecular response is observed in 15–30 % of patients. Mutations in the BCR::ABL kinase domain are one of the most common mechanisms for the development of resistance to tyrosine kinase inhibitors.Aim. To conduct a retrospective analysis of the BCR::ABL kinase domain mutational profile in patients with CML observed at the Russian Research Institute of Hematology and Transfusiology from 2012 to 2023. To assess the impact of mutations type and number on the rate of achieving a major molecular response (MMR). To study the risk of MMR loss depending on the therapy line and existing mutational status.Materials and methods. 1831 patients with CML were examined at different times. The mutational status of the BCR::ABL kinase domain was analyzed by direct Sanger sequencing. A standard cytogenetic study was carried out using GTG banding technology with the analysis of at least 20 metaphase plates.Results. Mutations in the BCR::ABL kinase domain were identified in 27.6 % of the total studied patients. The most common mutation, 6.3 % in the overall group or 22.7 % among patients with mutations, was the T315I mutation. Additional chromosomal aberrations (ACAs) were detected in Ph-positive cells in 20.5 % of patients, in Ph-negative clones in 3.9 % of cases (p = 0.0001). The frequency of ACAs detection did not statistically significantly differ (p = 0.25) between patients with BCR::ABL mutations (23.5 %) and with a negative mutation status (17.7 %), and the presence of mutations in the kinase domain did not correlate with ACAs in Ph-positive clones (p = 0.73). However, the frequency of T315I mutation detection in Ph-positive cells had significant differences: 40.9 % in combination with ACAs and 21 % without ACAs (p = 0.032). Patients with the T315I mutation had significantly worse MMR than patients with mutations in other BCR::ABL regions (p = 0.04) and patients without mutations (p = 0.02). The probability of MMR achieving did not differ significantly between patients with different numbers of BCR::ABL mutations (p = 0.14). Loss of MMR occurred more often in patients with mutations (p = 0.04) and not depend on the line of therapy (p = 0.03).Conclusion. For complete monitoring and optimal choice of therapy, CML patients require not only monitoring of BCR::ABL relative expression level, but also standard cytogenetic and analysis of the mutational status.